AstraZeneca Pharma India Q2 net profit dips 67% to Rs 9.13 cr

New Delhi: Drug firm AstraZeneca Pharma India Tuesday reported a 66.65 per cent dip in its net profit to Rs 9.13 crore for the quarter ended September 30, 2018. The company had posted a net profit of Rs 27.38 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a filing to BSE.

Company’s total revenue for the quarter under consideration stood at Rs 164.71 crore. It was Rs 166.75 crore for the same period year ago.

Shares of AstraZeneca Pharma India today closed at Rs 1,702.60 per scrip on BSE, up 0.70 per cent from the previous close.

  • Related Posts

    Civil society group SAM calls for greater transparency involving clinical trials

    The group had approached the Supreme Court, raising concerns on clinical trials in a Public Interest Litigation in 2012 Civil society group Swasthya Adhikar Manch (SAM) has called for greater…

    Different packaging, typos expose fake Mounjaro racket

    Gurugram: Colour dissimilarity to typographical errors… conspicuous differences in the packaging of counterfeit Mounjaro injections led the Drugs Control Office to crack down on the illicit sale and production of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Civil society group SAM calls for greater transparency involving clinical trials

    Civil society group SAM calls for greater transparency involving clinical trials

    Different packaging, typos expose fake Mounjaro racket

    Different packaging, typos expose fake Mounjaro racket

    To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

    To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    Rajasthan Bans 7 Sub-Standard Medicines

    Rajasthan Bans 7 Sub-Standard Medicines

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection